Challenges associated with metabolic syndrome

Pharmacotherapy

Volumn 26, Issue 12 II, 2006, Pages

  Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Cardiometabolic risk; Diabetes mellitus; DM; Metabolic syndrome; Obesity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAMIPRIL; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; AGED; ATHEROGENESIS; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFERENCE PAPER; COST OF ILLNESS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REPEATED DRUG DOSE; RISK FACTOR; RISK MANAGEMENT; SINGLE DRUG DOSE; THROMBOSIS; UNITED STATES;

EID: 33845259380     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12part2.209s     Document Type: Conference Paper

References (34)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2006;113:e85-151. (Erratum in Circulation 2006;113:e696.)
2. Davis SN. Contemporary strategies for managing cardiometabolic risk factors. J Manag Care Pharm 2006;12(12 suppl):S4-9.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486-97.
4. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC study). Am J Cardiol 2004;94:1249-54.
5. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293(15):1868-74.
6. Kohli P, Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006;295(7):819-21.
7. National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Risk assessment tool for estimating your 10-year risk of having a heart attack. Available from http://hp2010.nhlbihin.net/atpiii/calculator.asp. Accessed June 1, 2006.
8. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9.
9. Grundy SM, Cleeman JI, Daniels SR, et al, for the American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52. (Errata in Circulation. 2005;112(17):e297-8.)
10. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003;11:1223-31.
11. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
12. Anonymous. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet 2000;355:253-9.
13. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. Available from http://www.diabetes.org/diabetes-statistics/ prevalence.jsp. Accessed June 21, 2006.
14. American Diabetes Association. Complications of diabetes in the United States. Available from http://www.diabetes.org/diabetes-statistics/ complications.jsp. Accessed June 21, 2006.
15. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.
16. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006;29(suppl):S4-42.
17. Janssen I, Katzmarzyk PT, Ross R. Body Mass index, waist circumference, and health risk. Evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002;162:2074-9.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults, findings from the third national health and nutrition examination survey. JAMA 2002;287(3):356-9.
19. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27(10):2444-9.
20. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4):683-9.
21. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005;28(7):1769-78.
22. Reilly MP, Rader DJ. The metabolic syndrome. More than the sum of its parts. Circulation 2003;108:1546-51.
23. Kershaw EE, Flier JS. Obesity: special features. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89: 2548-56.
24. Goldstein BJ, Scalia R. Obesity: special feature. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89(6):2563-8.
25. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF kappa B signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-316.
26. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Circulation 1999;100:2473-9.
27. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-69.
28. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-903.
29. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288-95.
30. Powers PJ. Practice tips: how to intervene with overweight and obese patients. Am J Med 2005;118:936-8.
31. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-73.
32. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32(suppl 3):12-23.
33. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998;6(suppl 2):51S-209.
34. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.